Phebra Announces New Licensing Agreement with Medsenic for the Development of its Oral Arsenic Trioxide Formulation in the Treatment of Chronic Graft-Versus-Host and Autoimmune Diseases

You are now leaving a Phebra operated website. Links to all outside sites are provided as a resource to our visitors. Phebra accepts no responsibility for the content of sites that are not owned and operated by Phebra

Would you like to proceed?